Therapeutic Solutions International Reports Positive Clinical Data on QuadraMune® Reduction of SARS-CoV-2 Spike Protein Induced Inflammation

Rhea-AI Summary

TSOI announced positive results from a pilot clinical trial of QuadraMune, involving 20 subjects. The study showed that a seven-day treatment with QuadraMune significantly reduced the inflammatory cytokine interleukin-6 production in response to SARS-CoV-2 spike protein. Additionally, TSOI received a patent allowance for QuadraMune's immune modulatory properties against COVID-19. Company representatives emphasized the supplement's unique ability to alter immune responses, raising potential synergy with existing vaccines as new variants emerge.

Positive

• Pilot clinical trial demonstrated a significant reduction in interleukin-6 production in patients treated with QuadraMune.
• Patent allowance received for QuadraMune's properties related to immune modulation and COVID-19 inhibition.
• QuadraMune is positioned to potentially synergize with vaccination efforts against emerging COVID-19 variants.

Negative

• None.

Clinical Study Shows 7 Day Course of QuadraMune® Reduces COVID-19 Hyperinflammation Induced by Monocytes

OCEANSIDE, Calif.--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today positive results of a pilot clinical trial in 20 subjects.

In the study, ten subjects received placebo and ten received twice daily doses of QuadraMune for seven days. Blood monocytes were extracted and treated with SARS-CoV-2 spike protein in vitro for three time points. A significantly decreased production of the inflammatory cytokine interleukin-6 was reported at all three timepoints.

“QuadraMune is a unique nutraceutical supplement that suppresses inflammatory pathways associated with COVID-19 mortality, while at the same time inhibits immune suppressive enzymes such as indolamine 2,3 dioxygenase,” said Dr. Thomas Ichim, co-inventor of QuadraMune and Board Member of the Company. “As new variants of concern keep emerging, we believe it is necessary to continue exploring various immune modulatory strategies that potentially synergize with existing vaccination efforts.”

Last week Therapeutic Solutions International received a notice of allowance granting a patent on the immune modulatory and COVID-19 inhibiting properties of QuadraMune¹.

“In addition to studies performed by us and our collaborators, independent groups have published in the peer-reviewed literature that ingredients of QuadraMune possess activity against SARS-CoV-2 which are discussed in this press release²,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “We are currently working with numerous colleagues to collect clinical and laboratory data to optimize dosing and ideal combination therapies.”

“As a Company we pride ourselves in continually seeking to understand the mechanisms of action of our products,” said Timothy Dixon, President and CEO of TSOI and co-inventor of QuadraMune. “To our knowledge this is the only nutraceutical that actually alters immune cells of patients in order to decrease response to the spike protein.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/.

1 Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment | Business Wire
2 Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing (yahoo.com)

View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005264/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International

FAQ

What were the results of the recent TSOI clinical trial involving QuadraMune?

The clinical trial showed that QuadraMune significantly reduced interleukin-6 production in response to SARS-CoV-2 spike protein in 20 subjects.

What is the significance of the patent allowance granted to TSOI for QuadraMune?

The patent allowance confirms the unique immune modulatory and COVID-19 inhibiting properties of QuadraMune, which could enhance its market position.

How might QuadraMune affect COVID-19 treatment strategies?

QuadraMune may significantly alter immune responses, making it a potential candidate for combination therapies with existing vaccines as new variants emerge.

When was the patent for QuadraMune received by TSOI?

TSOI received the notice of allowance for the QuadraMune patent last week.

What is TSOI's focus in immune modulation?

TSOI is focused on immune modulation to treat several specific diseases, with a particular emphasis on COVID-19.